MA28400B1 - PYRAZOLO [1,5-A] PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF DEPENDENT DISEASES OF PROTEIN KINASE - Google Patents
PYRAZOLO [1,5-A] PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF DEPENDENT DISEASES OF PROTEIN KINASEInfo
- Publication number
- MA28400B1 MA28400B1 MA29182A MA29182A MA28400B1 MA 28400 B1 MA28400 B1 MA 28400B1 MA 29182 A MA29182 A MA 29182A MA 29182 A MA29182 A MA 29182A MA 28400 B1 MA28400 B1 MA 28400B1
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazolo
- pyrimidin
- treatment
- protein kinase
- amine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53822004P | 2004-01-22 | 2004-01-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28400B1 true MA28400B1 (en) | 2007-01-02 |
Family
ID=34807167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29182A MA28400B1 (en) | 2004-01-22 | 2006-07-10 | PYRAZOLO [1,5-A] PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF DEPENDENT DISEASES OF PROTEIN KINASE |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1708710A1 (en) |
JP (1) | JP2007519662A (en) |
KR (1) | KR20070009546A (en) |
CN (1) | CN1909908A (en) |
AR (1) | AR049769A1 (en) |
AU (1) | AU2005205915B2 (en) |
BR (1) | BRPI0507071A (en) |
CA (1) | CA2552885A1 (en) |
EC (1) | ECSP066718A (en) |
IL (1) | IL176737A0 (en) |
MA (1) | MA28400B1 (en) |
NO (1) | NO20063758L (en) |
PE (1) | PE20051089A1 (en) |
RU (1) | RU2006130003A (en) |
TN (1) | TNSN06226A1 (en) |
TW (1) | TW200528103A (en) |
WO (1) | WO2005070431A1 (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7563798B2 (en) * | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
GB0515026D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
CA2627623C (en) * | 2005-10-06 | 2014-04-22 | Schering Corporation | Methods for inhibiting protein kinases |
EP1931676B1 (en) | 2005-10-06 | 2011-11-16 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
MX2008008152A (en) | 2005-12-23 | 2008-09-12 | Ariad Pharma Inc | Bicyclic heteroaryl compounds. |
AU2007223865A1 (en) * | 2006-03-08 | 2007-09-13 | Novartis Ag | Use of pyrazolo[1,5A]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders |
WO2007109183A2 (en) * | 2006-03-20 | 2007-09-27 | Novartis Ag | Mutations and polymorphisms of fms-related tyrosine kinase 1 |
GB0606805D0 (en) * | 2006-04-04 | 2006-05-17 | Novartis Ag | Organic compounds |
GB0606804D0 (en) * | 2006-04-04 | 2006-05-17 | Novartis Ag | Organic Compounds |
KR20090073120A (en) * | 2006-09-28 | 2009-07-02 | 노파르티스 아게 | Pyrazolo[1,5-a]pyrimidine derivatives and their therapeutic use |
ATE502943T1 (en) | 2006-09-29 | 2011-04-15 | Novartis Ag | PYRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS |
EP1918291A1 (en) * | 2006-10-30 | 2008-05-07 | Novartis AG | 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators |
CA2689667A1 (en) * | 2007-06-07 | 2008-12-18 | Schering Corporation | Synthesis of substituted-3-aminopyrazoles |
WO2010118207A1 (en) | 2009-04-09 | 2010-10-14 | Schering Corporation | Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors |
EP2483263B1 (en) | 2009-09-30 | 2018-07-18 | Merck Sharp & Dohme Corp. | Heterocyclic compounds that are erk inhibitors |
UY33227A (en) * | 2010-02-19 | 2011-09-30 | Novartis Ag | PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6 |
BR122019024201B1 (en) | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | MACROCYCLIC COMPOUND AS TRK KINASE INHIBITORS, ITS USE, AND PHARMACEUTICAL COMPOSITION |
KR101856266B1 (en) * | 2010-08-09 | 2018-05-09 | 가부시키가이샤 에누비 켄코우겡큐쇼 | INHIBITOR OF CASEIN KINASE 1δ AND CASEIN KINASE 1ε |
WO2012023143A1 (en) | 2010-08-19 | 2012-02-23 | E. I. Du Pont De Nemours And Company | Fungicidal pyrazoles |
US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
WO2013077579A1 (en) * | 2011-11-25 | 2013-05-30 | 가톨릭대학교 산학협력단 | Pharmaceutical composition for preventing and treating ophthalmic disorders |
CN105906630B (en) * | 2015-04-06 | 2018-10-23 | 四川百利药业有限责任公司 | Two substitutional amine-group compounds of N- (1H- pyrazoles -5- bases) pyrimido pyrazoles -4,6- as FGFR inhibitor |
AU2016291676B2 (en) | 2015-07-16 | 2020-04-30 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
CN106588893A (en) * | 2016-12-01 | 2017-04-26 | 北京万全德众医药生物技术有限公司 | Preparation of vilazodone double oxide |
US11168090B2 (en) | 2017-01-18 | 2021-11-09 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
TWI812649B (en) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
TWI791053B (en) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof |
CA3087972C (en) | 2018-01-18 | 2023-01-10 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
US11603374B2 (en) | 2018-01-18 | 2023-03-14 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
CN111630054B (en) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | Substituted pyrazolo [3,4-d ] pyrimidine compounds as RET kinase inhibitors |
SG11202006701TA (en) * | 2018-01-29 | 2020-08-28 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
JP2022500383A (en) | 2018-09-10 | 2022-01-04 | アレイ バイオファーマ インコーポレイテッド | Condensed heterocyclic compound as a RET kinase inhibitor |
CN109836428A (en) * | 2019-02-27 | 2019-06-04 | 华东师范大学 | Pyrazoles [4,3-d] pyrimidine derivatives and purposes with immunosuppressive activity |
WO2021007094A1 (en) * | 2019-07-10 | 2021-01-14 | Musc Foundation For Research Development | Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury |
AU2020392087A1 (en) | 2019-11-25 | 2022-06-09 | Amgen Inc. | Heterocyclic compounds as Delta-5 Desaturase inhibitors and methods of use |
WO2023154282A1 (en) * | 2022-02-08 | 2023-08-17 | Theras, Inc. | Compounds having a t-structure formed by at least four cycles for use in the treatment of cancer and other indications |
CN114751910B (en) * | 2022-05-17 | 2023-02-24 | 重庆文理学院 | Compound capable of inducing cell megalophage death and preparation method and application thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3130633A1 (en) * | 1981-08-01 | 1983-02-17 | Basf Ag, 6700 Ludwigshafen | 7-AMINO-AZOLO (1,5-A) PYRIMIDINE AND FUNGICIDES CONTAINING THEM |
US5688949A (en) * | 1991-04-22 | 1997-11-18 | Otsuka Pharmaceutical Factory, Inc. | Pyrazolo 1,5-A!pyrimidine derivatives and anti-inflammatory agent containing the same |
ES2164153T3 (en) * | 1994-06-21 | 2002-02-16 | Otsuka Pharma Co Ltd | DERIVATIVE OF PIRAZOLO (1,5-A) PYRIMIDINE. |
JP3163413B2 (en) * | 1994-06-21 | 2001-05-08 | 株式会社大塚製薬工場 | Painkillers |
WO1998010590A1 (en) * | 1996-09-02 | 1998-03-12 | Sony Corporation | Device and method for transmitting video signal |
CN1701074A (en) * | 2002-09-04 | 2005-11-23 | 先灵公司 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
AU2003265901B2 (en) * | 2002-09-04 | 2006-09-14 | Pharmacopeia, Inc. | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
-
2005
- 2005-01-20 PE PE2005000080A patent/PE20051089A1/en not_active Application Discontinuation
- 2005-01-20 AR ARP050100208A patent/AR049769A1/en unknown
- 2005-01-21 TW TW094101852A patent/TW200528103A/en unknown
- 2005-01-21 KR KR1020067014683A patent/KR20070009546A/en not_active Application Discontinuation
- 2005-01-21 WO PCT/EP2005/000602 patent/WO2005070431A1/en active Application Filing
- 2005-01-21 AU AU2005205915A patent/AU2005205915B2/en not_active Ceased
- 2005-01-21 RU RU2006130003/15A patent/RU2006130003A/en not_active Application Discontinuation
- 2005-01-21 CA CA002552885A patent/CA2552885A1/en not_active Abandoned
- 2005-01-21 BR BRPI0507071-6A patent/BRPI0507071A/en not_active IP Right Cessation
- 2005-01-21 EP EP05706961A patent/EP1708710A1/en not_active Withdrawn
- 2005-01-21 JP JP2006550056A patent/JP2007519662A/en active Pending
- 2005-01-21 CN CNA2005800030379A patent/CN1909908A/en active Pending
-
2006
- 2006-07-06 IL IL176737A patent/IL176737A0/en unknown
- 2006-07-10 MA MA29182A patent/MA28400B1/en unknown
- 2006-07-21 EC EC2006006718A patent/ECSP066718A/en unknown
- 2006-07-21 TN TNP2006000226A patent/TNSN06226A1/en unknown
- 2006-08-22 NO NO20063758A patent/NO20063758L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PE20051089A1 (en) | 2006-01-25 |
AU2005205915B2 (en) | 2009-05-21 |
JP2007519662A (en) | 2007-07-19 |
KR20070009546A (en) | 2007-01-18 |
EP1708710A1 (en) | 2006-10-11 |
CA2552885A1 (en) | 2005-08-04 |
WO2005070431A1 (en) | 2005-08-04 |
NO20063758L (en) | 2006-10-23 |
RU2006130003A (en) | 2008-04-10 |
IL176737A0 (en) | 2006-10-31 |
ECSP066718A (en) | 2006-10-31 |
TNSN06226A1 (en) | 2007-12-03 |
CN1909908A (en) | 2007-02-07 |
AU2005205915A1 (en) | 2005-08-04 |
TW200528103A (en) | 2005-09-01 |
AR049769A1 (en) | 2006-09-06 |
BRPI0507071A (en) | 2007-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28400B1 (en) | PYRAZOLO [1,5-A] PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF DEPENDENT DISEASES OF PROTEIN KINASE | |
ATE417037T1 (en) | DIARYLUREA DERIVATIVES SUITABLE FOR THE TREATMENT OF PROTEIN KINASE-DEPENDENT DISEASES | |
WO2005123048A3 (en) | Screening methods using c-abl, fyn and syk in combination with tau protein | |
ES2354824T3 (en) | PIRAZOLO [1,5-A] USEFUL PYRIMIDINS AS INHIBITORS OF KINASE PROTEINS. | |
ZA200802998B (en) | Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases | |
ATE316077T1 (en) | PYRIMIDINE ACID DERIVATIVES SUITABLE FOR THE TREATMENT OF CRTH2-RELATED DISEASES | |
AU2003295644A1 (en) | Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor | |
HK1085740A1 (en) | Substituted 8'-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a] pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2- a] pyrimidin-6-one derivatives and their use against neurogenerative diseases | |
ATE405564T1 (en) | 1H-IMIDAZOÄ4,5-CUCHINOLIN DERIVATIVES FOR THE TREATMENT OF PROTEIN KINASE-DEPENDENT DISEASES | |
NL1026329A1 (en) | 2-Amino-pyridine derivatives useful for the treatment of diseases. | |
PL2004653T3 (en) | 3-substituted n-(aryl- or heteroaryl)-pyrazo[1,5-a]pyrimidines as kinase inhibitors | |
NO20041142L (en) | Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo [1,2-A] pyrimidin-5 (1H) one derivatives for neurodegenerative disorders | |
MA26951A1 (en) | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | |
FR2883182B1 (en) | VITAMIN COMPOSITION USEFUL IN THE TREATMENT OF OCULAR DISEASES | |
DK1902054T3 (en) | Pyrido [2,3-d] pyrimidine derivatives, preparation and therapeutic use thereof | |
IS7444A (en) | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | |
MY136822A (en) | Derivatives of [6, 7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide and their use as inhibitors upon the interaction of cams and leukointegrins | |
WO2007027233A3 (en) | Derivatives of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonic acid | |
ATE330596T1 (en) | USE OF 3-BEZOYLPHENYLACETIC ACID DERIVATIVES FOR THE TREATMENT OF RETINAL DISEASES | |
FR2835254B1 (en) | THIAZOLE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISEASES | |
ATE433983T1 (en) | THIADIBENZOAZULENDER DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
AU2003299206A8 (en) | Protein complexes involved in neurological diseases | |
PL371269A1 (en) | 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, the use thereof for producing drugs used in the treatment of immunological diseases | |
NL1028597A1 (en) | Formamide derivatives for the treatment of diseases. | |
ZA200050690B (en) | Use of modulators of the signal transduction pathway via the protein kinase fyn in the treatment of tumor diseases |